Xenter

The first-of-its-kind wireless guidewire designed for use during TAVR procedures. [Image courtesy of Xenter]Xenter today announced the recent unveiling of its dual-sensor investigational guidewire for transcatheter aortic valve replacement (TAVR).

Draper, Utah-based Xenter shared the technology at last month’s Transcatheter Cardiovascular Therapeutics (TCT) 2023 conference in San Francisco.

The first-of-its-kind wireless guidewire aims to collect an extensive range of real-time data points. It serves as an aortic regurgitation measurement (xAR) and clinical decision support tool. Xenter says it significantly enhances the prediction of paravalvular leak (PVL) during TAVR.

According to a news release, the company designed the guidewire for comprehensive data collection and analysis. It facilitates data necessary for novel AI decision-making tools. The company aims to enable better-informed clinical decisions and improve patient outcomes. The company des…

Xenter this week announced that it has appointed Tony Collins as chief financial officer.

Collins most previously served as CFO at Zimmer Biomet and was responsible for all strategic and financial planning, business development, accounting and internal controls. He has held numerous leadership roles at Zimmer Biomet, including VP of finance, corporate controller and chief accounting officer and VP of finance for global operations and supply chain. Prior to joining Zimmer Biomet Collins held numerous executive leadership roles at Guidant/Boston Scientific.

“I am very excited to join Xenter’s fast-growing and innovative executive team,” Collins said in a news release. “I believe Xenter will transform interventional medicine by developing a platform using smart technologies, ultimately giving patients control of their medical data. With this new role, I am eager to use my industry knowledge and experience to further guide and develop Xenter’s data, therapeutic, an…

Xenter today announced that it has appointed Mark Turco as president of its Xenter Medical Technologies business unit.

Turco most recently served as executive VP of research & development and global chief medical officer at Sirtex Medical. He has also served as chief medical officer of Covidien and later the VP and chief medical officer of Medtronic’s aortic, peripheral and vascular divisions. Turco has also held leadership roles at the University of Pennsylvania’s Penn Center for Innovation and had a clinical practice at Washington Adventist Hospital.

“I am very excited to join Xenter in this pivotal leadership role,” Turco said in a news release. “I look forward to aiding in the development of medical technologies using Xenter’s three pillars: medical devices, health data, and therapeutic drugs. I am joining a globally recognized and experienced team that has been tasked with transforming the collection of procedural and patient data usi…